Island Pharmaceuticals (ASX:ILA) has strengthened its position in the United States biodefence research network through a new collaborative agreement aimed at accelerating the development of its antiviral drug candidate, Galidesivir, for the treatment of Marburg virus disease.
Latest Video
New Stories
-
New Zealand's pre-election Budget boosts health spending, but Pharmac misses out
May 29, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 29 May
May 28, 2026 - - Podcast -
AusBiotech unites conferences under the banner of the 'Biggest Week' in biotech
May 28, 2026 - - Australian Biotech -
Research highlighting gaps leaving some communities at greater risk as flu
May 28, 2026 - - Latest News -
A fraught process but also an opportunity to reintroduce ideas sidelined by the review
May 28, 2026 - - Latest News -
Single infusion of Lilly gene editing cuts cholesterol with the company planning long-term study
May 27, 2026 - - Latest News -
ARCS launches national partnership to boost public clinical research sites
May 27, 2026 - - Latest News
